Back

Remepy appoints Teva veteran Eran Harary as chief medical officer

Verifying
  • Remepy appointed Eran Harary, MD, as chief medical officer effective October 1, 2026.
  • Q4 2026 marks the expected start of Hybridopa’s global Phase III development.
  • Harary previously held senior research and development roles at Teva Pharmaceuticals, Lundbeck, Pfizer, and Alcobra Pharma.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.